德克萨斯州商业保险宫颈癌患者的平均直接医疗费用
本研究基于2011-2014年美国MarketScan数据库,纳入475例德克萨斯州新诊断宫颈癌的商业保险患者,采用倾向评分匹配法匹配无癌对照,估算诊断后2年内平均医疗费用。结果显示病例组第一年和第二年平均费用分别为60,828美元和37,721美元,对照组分别为9,982美元和10,066美元,差异费用分别为50,846美元和27,656美元。
要点
- 宫颈癌病例诊断后第一年平均医疗费用为60,828美元,第二年为37,721美元。
- 对照组第一年和第二年平均费用分别为9,982美元和10,066美元。
- 宫颈癌差异费用第一年为50,846美元,第二年为27,656美元,费用在诊断后1至5个月间急剧下降后趋于稳定。
核心结论
- 德克萨斯州宫颈癌相关的平均直接医疗费用相当可观,这些数据将作为德克萨斯州人乳头瘤病毒(HPV)相关癌症费用模型和HPV疫苗接种推广经济评估的关键费用参数。
研究设计与样本
- 研究基于2011-2014年美国MarketScan去标识化数据库,纳入475例德克萨斯州新诊断宫颈癌的商业保险患者(病例),采用两步倾向评分匹配法匹配无癌对照,并按索引日期匹配。
- 使用广义线性模型计算2年随访期内删失月份的费用,通过从病例费用中减去对照费用来评估差异费用。
主要发现
- 病例组第一年和第二年平均医疗费用分别为60,828美元和37,721美元,对照组分别为9,982美元和10,066美元。
- 宫颈癌第一年和第二年差异费用分别为50,846美元和27,656美元。
- 与较高月度宫颈癌费用相关的主要因素包括诊断前6个月内较高的Charlson合并症指数评分、诊断前6至3个月间较高的医疗费用以及居住在德克萨斯州西部。
- 宫颈癌患者费用在诊断后第1个月至第5个月间急剧下降后趋于稳定,而对照组费用在整个随访期内保持稳定。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the mean cervical cancer medical care costs for patients enrolled in commercial insurance in Texas. Cost is represented by insurer and patient payments for care. METHODS: We estimated the mean medical care costs during the first 2years after the index diagnosis date for patients with cervical cancer (cases). Cases were identified using claims-based International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9), diagnosis codes and matched to controls without a claims-based ICD-9 code for cancer using a 2-step propensity score matching method. Index dates for the cases were randomly assigned to potential controls, and cases and controls were matched by index date. Data for cancer cases and controls were obtained from the de-identified 2011-2014 U.S. MarketScan databases. A generalized linear model was employed to compute the cost for censored months during the 2-year follow-up period. Differential costs were assessed by subtracting the medical costs incurred by controls from those incurred by cases. RESULTS: During 2011-2014, 475 commercially insured Texas patients with newly diagnosed cervical cancer met the inclusion criteria. The first-year and second-year mean medical costs were $60,828 and $37,721 for cases and $9982 and $10,066 for controls, respectively. The differential costs of cervical cancer for the first and second years were $50,846 and $27,656, respectively. The major correlates of higher monthly cervical cancer costs were higher Charlson Comorbidity Index score during 6months period prior to diagnosis, higher healthcare costs between 6months and 3months prior to diagnosis, and residence in the western region of Texas. Costs for cervical cancer patients decreased steeply between month 1 and month 5 after diagnosis and then were stable, while costs for the control group were stable throughout the follow-up period. CONCLUSIONS: Mean direct medical costs associated with cervical cancer in Texas were substantial. These data will serve as key cost parameters in models of costs associated with human papillomavirus (HPV)-related cancers in Texas and the economic evaluation of HPV vaccination dissemination in Texas.
引用
- Lairson DR, Fu S, Chan W, et al. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas. Gynecol Oncol. 2017. PMID: 28196673. doi:10.1016/j.ygyno.2017.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。